Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.53 |
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | RECQL | P46063 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.51 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.51 |
| ▸ | RELA | Q04206 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16532912 | 0.83 | MEN1 (0.66) | MEN1KMT2AMAPTLMNARECQL | |
| SCHEMBL21234688 | 0.77 | MEN1 (0.46) | MEN1KMT2AMAPTLMNARECQL | |
| SCHEMBL18032712 | 0.76 | MEN1 (0.57) | MEN1KMT2AMAPTLMNARECQL | |
| SCHEMBL21160097 | 0.74 | MEN1 (0.47) | MEN1KMT2AMAPTLMNARECQL | |
| SCHEMBL21234910 | 0.73 | MEN1 (0.49) | MEN1KMT2AMAPTLMNARECQL | |
| SCHEMBL21036989 | 0.73 | MEN1 (0.49) | MEN1KMT2AMAPTLMNARECQL | |
| SCHEMBL21023357 | 0.73 | MEN1 (0.66) | MEN1KMT2AMAPTLMNARECQL | |
| SCHEMBL27983252 | 0.72 | MEN1 (0.82) | MEN1KMT2AMAPTLMNARECQL | |
| SCHEMBL14613096 | 0.72 | MEN1 (0.69) | MEN1KMT2AMAPTLMNARECQL | |
| SCHEMBL20994201 | 0.72 | MEN1 (0.53) | MEN1KMT2AMAPTLMNARECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11365203-B2 | Fluorescent dye and preparation method and use thereof | FLUORESCENCE DIAGNOSIS (SHANGHAI) BIOTECH COMPANY LTD. (CN) | 2022-06-21 | — | — | US | disclosed |
| US-20190241584-A1 | FLUORESCENT DYE AND PREPARATION METHOD AND USE THEREOF | EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2019-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190241584-A1 | FLUORESCENT DYE AND PREPARATION METHOD AND USE THEREOF | DNASE1, POLRMT, DCLRE1B | MEN1 3709/4885KMT2A 3545/4885MAPT 2048/4885 |
| US-11365203-B2 | Fluorescent dye and preparation method and use thereof | DNASE1, POLRMT, DCLRE1B | MEN1 3709/4885KMT2A 3545/4885MAPT 2048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.